AMCP Market Insights: Payer best practices for timely diagnosis and optimal management of idiopathic hypersomnia
Idiopathic hypersomnia (IH) is a chronic, neurologic disorder with a primary symptom of excessive daytime sleepiness. There are challenges to timely, accurate diagnosis of IH and, therefore, to optimal management. To better understand these challenges and identify opportunities, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2024. Key insights from the discussion related to addressing diagnostic challenges in IH, making coverage decisions for medications used in IH, and implementing coverage criteria for medications used in IH. Suggested payer best practices in IH also emerged from the discussion.
Authors
- Ryan J. Haumschild
- Michael Kobernick
- Bridget M. Flavin
- Denise Wolff
- Diana Kimmel
- Farzana Rahman (ORCID: https://orcid.org/0009-0000-6763-6802)
- Zachary Contreras
Institutions
- Emory Healthcare (US)
- Sharp Memorial Hospital (US)
- Caritas Hospital (IN)
- Blue Cross and Blue Shield of Kansas City (US)
- Hypersomnia Foundation (US)
- University of Minnesota, Duluth (US)
- Blue Cross and Blue Shield of Florida Foundation (US)
- Edelweiss Connect (Switzerland) (CH)
- Winship Cancer Institute
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-08-30
- DOI
- https://doi.org/10.18553/jmcp.2025.31.9-a.s1
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00